XML 31 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Fair Value Assumptions, Expected Dividend Rate     0.00%    
Derivative, Gain (Loss) on Derivative, Net $ 12,661 $ (26,887) $ 12,544 $ (28,394)  
Cash Equivalents, at Carrying Value 0   0   $ 0
Payments to Acquire Available-for-sale Securities     2,549,179  
Proceeds from Sale of Available-for-sale Securities     720,000  
Available-for-sale Securities, Gross Realized Gain (Loss) (92) (92)  
Available-for-sale Securities, Gross Unrealized Gain (Loss)     (3,163)  
Available-for-sale Securities 1,825,923   1,825,923    
Goodwill, Impairment Loss $ 0 $ 404,169 $ 404,169
Private Placement [Member] | Series B Preferred Stock [Member] | Strategic Bio Partners [Member] | Debt Settlement [Member]          
Class of Warrant or Right, Issued     295,945    
Private Placement [Member] | Series B Preferred Stock [Member] | Placement Agent Warrants [Member]          
Class of Warrant or Right, Issued     127,346